CJC-1295 (No DAC) + Ipamorelin 10 MG

CJC-1295 (No DAC) and Ipamorelin are peptide compounds commonly studied in the field of synthetic peptide research for their potential biological effects on growth hormone secretion and other metabolic pathways. This product is intended for use in laboratory settings only, specifically within academic, pharmaceutical, or industrial research contexts.

Research Context

CJC-1295 is a non-acylated analog of GHRH (Growth Hormone-Releasing Hormone) designed to enhance growth hormone (GH) secretion without the associated vasopressin-like effects seen with traditional GHRH derivatives. It operates through a distinct mechanism that bypasses some of the regulatory feedback mechanisms, leading to prolonged GH release. Ipamorelin, a selective GH-releasing peptide, specifically targets the pituitary gland to stimulate GH secretion while minimizing the influence of other growth factors, such as IGF-1. Together, these peptides are frequently explored for their potential in studying hormone regulation, aging research, and metabolic health in controlled experimental environments.

Research Overview

The combination of CJC-1295 (No DAC) and Ipamorelin has been investigated in preclinical and early-stage research settings for its synergistic effects on GH and IGF-1 dynamics. CJC-1295’s prolonged GH release may enhance research into muscle protein synthesis, bone metabolism, and tissue regeneration under controlled conditions. Ipamorelin’s specificity ensures focused GH stimulation, which can be useful for studying pituitary function and compensatory mechanisms in various experimental models. Both peptides have been utilized in studies assessing their impact on physiological aging, metabolic responses, and potential therapeutic applications in disease models, primarily within in vitro and animal studies.

Key Research Focus Areas

• Growth Hormone (GH) Secretion Regulation – Investigation into mechanisms of GH release and feedback inhibition in pituitary models.
• Metabolic and Anabolic Effects – Exploration of GH and IGF-1 interactions on muscle growth, bone density, and tissue repair.
• Aging Research – Study of peptide-induced GH responses and their potential anti-aging effects in controlled experimental settings.
• Drug Discovery and Pharmacology – Analysis of peptide binding, stability, and metabolic clearance in preclinical models.
• Comparative Pharmacology – Evaluation of synergistic or antagonistic effects when combined with other GH-releasing peptides.

Safety and Compliance Notice

This product is intended solely for use in research laboratories to study biological mechanisms under the direct supervision of qualified personnel. The administration of these peptides in human or animal subjects is strictly prohibited and is considered outside the scope of this product’s intended use. Potential risks associated with improper handling or unintended exposure include adverse reactions, misinterpretation of experimental results, or legal consequences. Users must adhere to all applicable regulatory guidelines and ensure compliance with research ethics standards.